60 Participants Needed

Abiraterone + Prednisone + Apalutamide for Prostate Cancer

Paul G. Corn | MD Anderson Cancer Center
Overseen ByPaul Corn
Age: 18+
Sex: Male
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
Must be taking: Antiandrogens
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well abiraterone acetate, prednisone, and apalutamide work in treating patients with hormone-naive prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate and apalutamide may lessen the amount of androgen made by the body.

Will I have to stop taking my current medications?

The trial requires that medications known to lower the seizure threshold be stopped or replaced at least 4 weeks before starting the study. Additionally, if you are on anti-androgens with LHRH agonists, these must be stopped within 2 weeks before starting the trial.

What data supports the effectiveness of the drug combination Abiraterone, Prednisone, and Apalutamide for prostate cancer?

Research shows that Abiraterone combined with Prednisone improves survival and delays disease progression in men with metastatic prostate cancer, especially when used with androgen deprivation therapy. Although Apalutamide is not directly mentioned in these studies, it is another drug used to treat prostate cancer, suggesting potential benefits when combined with Abiraterone and Prednisone.12345

Is the combination of Abiraterone, Prednisone, and Apalutamide safe for humans?

Abiraterone combined with prednisone is generally safe for treating prostate cancer, but it can sometimes cause liver issues and hormonal imbalances. Patients may experience increased liver enzymes and conditions like mineralocorticoid excess (too much of certain hormones) and adrenal insufficiency (not enough hormone production by the adrenal glands).26789

What makes the drug combination of Abiraterone, Prednisone, and Apalutamide unique for prostate cancer?

This drug combination is unique because it combines Abiraterone and Apalutamide, which both target androgen (male hormone) pathways, with Prednisone, a steroid that helps manage side effects, potentially offering a more comprehensive approach to treating prostate cancer compared to using these drugs separately.136710

Research Team

Paul G. Corn | MD Anderson Cancer Center

Paul Corn

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

Men with hormone-naive metastatic prostate cancer who can perform daily activities with some limitations (ECOG <=2) and have certain high-risk factors like a Gleason score >=8. They must not have small cell prostate cancer, heart issues, or conditions increasing bowel perforation risk. Participants need to be able to take oral medication and agree to use contraception.

Inclusion Criteria

My platelet count is at least 100,000 without transfusions in the last 3 months.
I stopped taking any medication that could increase my risk of seizures 4 weeks ago.
Serum bilirubin < 1.5 x institutional upper limit of normal (IULN) (except for patients with known Gilbert's disease if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible)
See 13 more

Exclusion Criteria

I have had limited treatment for my metastatic prostate cancer before starting this trial.
I have untreated spinal cord compression that causes symptoms.
I do not have an active infection or a condition that prevents steroid use. I do not have HIV/AIDS.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive abiraterone acetate, prednisone, and apalutamide. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.

12 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
Follow-up at 30 days and then up to 6 months

Treatment Details

Interventions

  • Abiraterone Acetate
  • Apalutamide
  • Prednisone
Trial Overview The trial is testing the combination of abiraterone acetate, prednisone, and apalutamide in treating men whose prostate cancer has spread but haven't had hormonal treatments yet. The goal is to see if these drugs can reduce the body's production of hormones that fuel tumor growth.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (abiraterone acetate, prednisone, apalutamide)Experimental Treatment3 Interventions
Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.

Abiraterone Acetate is already approved in United States, European Union, Canada, Japan for the following indications:

🇺🇸
Approved in United States as Zytiga for:
  • Metastatic castration-resistant prostate cancer
  • Metastatic high-risk castration-sensitive prostate cancer
🇪🇺
Approved in European Union as Zytiga for:
  • Metastatic castration-resistant prostate cancer
  • Newly diagnosed high-risk metastatic hormone-sensitive prostate cancer
🇨🇦
Approved in Canada as Zytiga for:
  • Metastatic castration-resistant prostate cancer
  • Metastatic castration-sensitive prostate cancer
🇯🇵
Approved in Japan as Zytiga for:
  • Prostate cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Findings from Research

In a study involving 1919 patients with metastatic prostate cancer, the addition of abiraterone acetate to standard androgen deprivation therapy significantly improved overall survival, with a median survival of 76.6 months compared to 45.7 months for standard care alone.
Combining both abiraterone and enzalutamide did not provide additional survival benefits over abiraterone alone, and it was associated with higher rates of severe side effects, suggesting that this combination should be avoided in long-term treatment plans.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.Attard, G., Murphy, L., Clarke, NW., et al.[2023]
Oral abiraterone acetate (Zytiga®) significantly improves overall survival and progression-free survival in patients with metastatic castration-resistant prostate cancer (CRPC) when used with prednisone, compared to a placebo.
The treatment is specifically effective for patients who have already undergone docetaxel-containing chemotherapy, highlighting its role as a subsequent therapy in advanced prostate cancer management.
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.Scott, LJ., Yang, LPH., Lyseng-Williamson, KA.[2021]
In a phase 3 trial with 1088 patients, abiraterone acetate plus prednisone significantly improved overall survival compared to placebo plus prednisone, with a median survival of 34.7 months versus 30.3 months, indicating its efficacy in treating chemotherapy-naive castration-resistant prostate cancer.
The treatment was associated with a manageable safety profile, although there were some increased risks of grade 3-4 adverse events, such as cardiac disorders and elevated liver enzymes, suggesting that while effective, monitoring for side effects is important.
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.Ryan, CJ., Smith, MR., Fizazi, K., et al.[2022]

References

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. [2023]
Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer. [2021]
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. [2022]
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. [2023]
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. [2022]
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. [2022]
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. [2022]
Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. [2020]
Abiraterone-Induced Endocrinopathies. [2023]
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security